Goldman Sachs
CYCN icon

Goldman Sachs’s Cyclerion Therapeutics CYCN Stock Holding History

Goldman Sachs’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,195
Closed -$135K – 6491
2021
Q3 		$135K Buy
2,195
+379
+21% +$24.8K ﹤0.01% 5847
2021
Q2 		$141K Sell
1,816
-187
-9% -$11.7K ﹤0.01% 5861
2021
Q1 		$112K Buy
2,003
+163
+9% +$12.2K ﹤0.01% 5811
2020
Q4 		$112K Buy
1,840
+1,106
+151% +$75.4K ﹤0.01% 5276
2020
Q3 		$89K Sell
734
-826
-53% -$94.4K ﹤0.01% 5108
2020
Q2 		$184K Buy
1,560
+636
+69% +$53.2K ﹤0.01% 4818
2020
Q1 		$49K Sell
924
-1,088
-54% -$77.6K ﹤0.01% 5055
2019
Q4 		$109K Sell
2,012
-377
-16% -$35.2K ﹤0.01% 5035
2019
Q3 		$579K Sell
2,389
-1,499
-39% -$324K ﹤0.01% 4373
2019
Q2 		$890K Buy
+3,888
New +$1.1M ﹤0.01% 4067

Other funds holding CYCN

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs's CYCN Position: Q4 2021 in Review

Goldman Sachs sold out of Cyclerion Therapeutics (CYCN) in Q4 2021, closing a stake of 2,195 shares — an estimated $135K sold.

Goldman Sachs first reported a position in CYCN in Q2 2019 and held it in 10 quarters. The position peaked at $890K in Q2 2019. 56 funds tracked by Wall St. Rank hold CYCN as of Q4 2021.

  • Goldman Sachs reported no remaining Cyclerion Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Goldman Sachs sold 2,195 Cyclerion Therapeutics shares in Q4 2021, an estimated $135K.
  • Goldman Sachs first reported a position in Cyclerion Therapeutics in Q2 2019 and held it in 10 quarters.
  • Goldman Sachs's Cyclerion Therapeutics position peaked at $890K in Q2 2019.
  • 56 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q4 2021.

Based on Goldman Sachs's 13F filing for Q4 2021, filed 14 Feb 2022.